Home · Pharmacies
Compounding pharmacies · 503A & 503BCompounding pharmacies behind online tirzepatide (2026)
Most compounded tirzepatide sold online in 2026 is dispensed by state-licensed 503A pharmacies, because the FDA ended shortage-period compounding by 503B outsourcing facilities on March 19, 2025. Of the six pharmacies we profile, only Empower operates an FDA-registered 503B facility, and Empower received an FDA warning letter on September 18, 2026 over tirzepatide/niacinamide and semaglutide/B12 products. Ask your telehealth program to name its pharmacy before you pay.
Six pharmacies, checked against FDA records
| Pharmacy | Location | Type | Recent FDA record |
|---|---|---|---|
| Empower Pharmacy | 503A: 7601 N. Sam Houston Pkwy W., Houston, TX 77064 | 503A pharmacy and 503B outsourcing facility | Warning letters 738238 (Sept 18, 2026), 700964 and 700962 (April 2, 2025); Form 483s in 2023, 2024 and 2025 |
| Hallandale Pharmacy | 2666 SW 36th St, Fort Lauderdale, FL 33312 | 503A compounding pharmacy | Form 483 issued June 13, 2025; FMD-145 letter November 20, 2025 |
| MediVera Compounding Pharmacy | 5225 Crooks Rd, Troy, MI 48098 | 503A compounding pharmacy | None found |
| Red Rock Pharmacy | 863 W 450 S, Ste 101, Springville, UT | 503A compounding pharmacy | Form 483 issued July 31, 2026 (inspection July 21–31, 2026), 10 observations |
| Strive Pharmacy | 1275 E Baseline Rd #104, Gilbert, AZ 85233 | 503A compounding pharmacy | Form 483, Boerne TX, Sept 8, 2023; warning letter 639220 (Aug 29, 2022) closed out May 13, 2026 |
| Absolute Pharmacy | 16011 N. Nebraska Ave., Suite 103, Lutz, FL 33549 | 503A compounding pharmacy (FDA: de-registered as an outsourcing facility) | None found; warning-letter close-out and FMD-145 letter July 14, 2021 |
Correction, October 14, 2026: earlier editions of these profiles carried founding years, accreditations, locations and provider links that we could not support from public records. Every profile has been rewritten from FDA records and the pharmacies' own pages; corrections are noted on each profile.
503A vs 503B in one minute
A 503A pharmacy compounds patient-specific prescriptions and answers mainly to state boards. A 503B outsourcing facility registers with the FDA, follows current good manufacturing practice and can make larger batches — but only from bulk substances the FDA allows. The FDA proposed on April 30, 2026 to keep tirzepatide, semaglutide and liraglutide off that list; the comment period closed July 30, 2026. Full guide: 503A vs 503B.
Why "tirzepatide with B12" keeps coming up
Several pharmacies sell tirzepatide or semaglutide combined with B12, glycine or niacinamide. The FDA said in April 2026 that adding B12 to semaglutide does not automatically make it different from an approved drug, and its September 2026 Empower letter named tirzepatide/niacinamide. Read the additives explainer.
Programs that name their pharmacy
NexLife, our #1-ranked provider, names Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA) on its standard plan page; its microdose pages listed Absolute, Hallandale, Red Rock, Empower and Strive when we read them on September 17, 2026. IVIM Health names six pharmacies, including Empower and Hallandale, and says yours may change from order to order. See the full rankings.
Frequently asked questions
What is the difference between a 503A pharmacy and a 503B outsourcing facility?
A 503A pharmacy compounds for individual patients on prescriptions and is overseen mainly by state boards of pharmacy. A 503B outsourcing facility registers with the FDA, is inspected on a risk-based schedule and must follow current good manufacturing practice. Neither makes a compounded drug FDA-approved.
Can 503B outsourcing facilities compound tirzepatide in 2026?
Not from bulk drug substance in the ordinary course. The FDA ended its shortage-period enforcement discretion for 503B facilities on March 19, 2025, and on April 30, 2026 proposed to keep tirzepatide off the 503B bulks list; no final decision had been published as of October 14, 2026.
Which pharmacies have FDA warning letters in 2025–2026?
Of the six we profile, Empower Pharmacy received warning letters on April 2, 2025 and September 18, 2026. Red Rock Pharmacy received a Form 483 on July 31, 2026 and Hallandale Pharmacy one on June 13, 2025. Strive's 2022 warning letter was closed out on May 13, 2026.
How do I find out which pharmacy made my compounded tirzepatide?
The dispensing pharmacy is printed on the prescription label. If your program will not name it before you pay, treat that as a reason to ask more questions.
Sources
- FDA: registered outsourcing facilities (updated September 30, 2026)
- FDA: compounding inspections, recalls and other actions
- FDA: policies for compounders as GLP-1 supply stabilizes
- FDA: proposal to exclude GLP-1s from the 503B bulks list (April 30, 2026)
- FDA: Compounding and the FDA, questions and answers